Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Kinnate Biopharma Inc. (KNTE)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 43,711,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Kinnate is a clinical stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for genomically defined cancers. Co.'s focus is on three patient populations: those with cancers that harbor known oncogenic drivers with no available targeted therapies; those with genomically well-characterized tumors that have resistance to available treatments; and those whose tumors have acquired resistance over the course of therapy to available treatments. Co.'s product candidates are KIN002787, which is for the treatment of patients with lung cancer, melanoma and other solid tumors; and KIN-3248, which is targeting cancer-associated alterations in FGFR2.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 9,292,200 9,292,200
Total Buy Value $0 $0 $25,488,272 $25,488,272
Total People Bought 0 0 4 4
Total Buy Transactions 0 0 12 12
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 62
  Page 1 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Krishnamohan Neha CHIEF FINANCIAL OFFICER   •       –      –    2024-04-03 4 D $0.00 $0 D/D (64,087) 0     -
   Orbimed Capital Llc Director   –       •       •   2024-04-03 4 D $0.00 $0 I/I (8,009,729) 0     -
   Flaherty Keith T.   –       •      –    2024-04-03 4 D $0.00 $0 D/D (66,377) 0     -
   Gordon Carl L Director   –       •       •   2024-04-03 4 D $0.00 $0 I/I (8,009,729) 0     -
   Foresite Capital Opportunity Fund V, L.p. 10% Owner   –       –       •   2024-04-03 4 D $0.00 $0 I/I (13,718,311) 0     -
   Farzan Nima CHIEF EXECUTIVE OFFICER   •       •      –    2024-04-03 4 D $0.00 $0 D/D (2,186) 0     -
   Tananbaum James B.   –       •       •   2024-04-03 4 D $0.00 $0 I/I (13,718,311) 0     -
   Meltz Mark A COO GENERAL COUNSEL SECRETARY   •       –      –    2024-04-03 4 D $0.00 $0 D/D (27,578) 0     -
   Williams Richard Thomas CHIEF MEDICAL OFFICER   •       –      –    2024-03-01 4 D $2.59 $1,445 D/D (558) 67,588     -
   Krishnamohan Neha CHIEF FINANCIAL OFFICER   •       –      –    2024-03-01 4 D $2.59 $3,901 D/D (1,506) 64,087     -
   Meltz Mark A COO GENERAL COUNSEL SECRETARY   •       –      –    2024-03-01 4 D $2.59 $1,445 D/D (558) 27,578     -
   Meltz Mark A COO General Counsel Secretary   •       –      –    2023-12-01 4 D $2.25 $1,217 D/D (541) 28,136     -
   Williams Richard Thomas Chief Medical Officer   •       –      –    2023-12-01 4 D $2.25 $1,217 D/D (541) 68,146     -
   Krishnamohan Neha Chief Financial Officer   •       –      –    2023-12-01 4 D $2.25 $3,283 D/D (1,459) 65,593     -
   Williams Richard Thomas Chief Medical Officer   •       –      –    2023-09-01 4 D $2.35 $1,271 D/D (541) 68,687     -
   Meltz Mark A COO General Counsel Secretary   •       –      –    2023-09-01 4 D $2.35 $1,271 D/D (541) 28,677     -
   Krishnamohan Neha Chief Financial Officer   •       –      –    2023-09-01 4 D $2.35 $3,429 D/D (1,459) 67,052     -
   Williams Richard Thomas Chief Medical Officer   •       –      –    2023-06-01 4 D $4.30 $2,326 D/D (541) 69,228     -
   Krishnamohan Neha Chief Financial Officer   •       –      –    2023-06-01 4 D $4.30 $6,274 D/D (1,459) 68,511     -
   Meltz Mark A COO General Counsel Secretary   •       –      –    2023-06-01 4 D $4.30 $2,326 D/D (541) 29,218     -
   Foresite Capital Opportunity Management V, Llc 10% Owner   –       –       •   2023-05-08 4 B $2.80 $4,984,000 I/I 1,780,000 520,711 1.5     -
   Tananbaum James B. Director   –       •       •   2023-05-08 4 B $2.80 $4,984,000 I/I 1,780,000 520,711 2.25     -
   Gordon Carl L Director   –       •       •   2023-05-05 4 B $2.82 $2,766,485 I/I 981,023 1,368,338 2.25     -
   Orbimed Capital Llc Director   –       •       •   2023-05-05 4 B $2.82 $2,766,485 I/I 981,023 1,368,338 2.25     -
   Gordon Carl L Director   –       •       •   2023-05-04 4 B $2.75 $1,319,750 I/I 479,909 877,827 2.25     -
  62 Records found
  1  2  3   
  Page 1 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us